Viewing nowTevisil Tablet (Terbinafine Hydrochloride)
Terbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Os Korea Pharmaceutical Co., Ltd.

MFDS item code 200401589 · Notified 2004.11.20 · Insurance code 629700210
Treatment of onychomycosis, dermatomycosis (tinea pedis, tinea corporis, etc.), and tinea capitis
This medication is used for the treatment of dermatophyte infections such as tinea pedis, tinea corporis, and tinea capitis caused by dermatophytes in adults. It is also effective for the treatment of tinea capitis in children.
Administer terbinafine at 125 mg per dose twice daily or 250 mg per dose once daily. The treatment periods according to the condition are as follows. 1) Dermatophytosis Tinea pedis (interdigital type, plantar type/moccasin type): 2~6 weeks Tinea corporis: 2∼4 weeks Tinea cruris: 2~4 weeks 2) Onychomycosis Administer for 6 weeks~3 months in general. The treatment period may be shortened to 3 months or less in patients with infection of the fingernails or relatively small toes, or in younger patients. A treatment period of 3 months is usually sufficient for toenail infections, but some patients may require 6 months or longer. The treatment period may be longer in patients whose nails grow slowly. For patients with creatinine clearance below 50 mL per minute, reduce the daily dose by 1/2.
Administer to children aged 2 years and older. Administration is not recommended for children under 2 years of age because there is no experience with use in this age group. Tinea capitis: 4 weeks Tinea capitis occurs mainly in children. To prevent recurrence of infection, treatment should be given regularly for the appropriate prescribed period. Body weight below 20 kg (under 5 years): Administer 62.5 mg per dose once daily. Because experience with use is limited, the decision to administer should be based on consideration of the benefits and risks of treatment. Body weight 20~40 kg (5~12 years): Administer 125 mg per dose once daily. Body weight over 40 kg (over 12 years): Administer 250 mg per dose once daily.
This medication is not recommended for patients with chronic liver disease or active liver disease. The presence of liver disease must be confirmed before administration, and liver function tests should be performed regularly. If symptoms of liver dysfunction appear, the medication should be discontinued immediately and a physician should be informed. Serious liver damage, such as hepatic failure, may rarely occur. This medication should not be used by individuals with hypersensitivity or certain blood disorders, patients with severe renal failure, infants under 2 years of age, or nursing mothers. Patients with lactose intolerance should also avoid this medication. Caution should be exercised when administering to patients with reduced renal function, the elderly, and underweight children. Serious skin reactions may occur, so skin conditions should be carefully monitored, and the medication should be discontinued immediately if any abnormal symptoms arise. Regular checks of liver function, blood tests, and skin conditions should be performed during the use of this medication. Symptoms such as dizziness may arise when driving or operating machinery, so caution is advised. There may be interactions with other medications, so if you are taking any other medications, be sure to inform healthcare professionals. Use this medication with caution during pregnancy or in women who could become pregnant, and avoid use in nursing mothers. In the case of overdose, symptoms such as headache, nausea, and dizziness may occur, and you should seek medical help immediately. This medication should be stored out of the reach of children, protected from direct sunlight, and stored at room temperature.
Liver and biliary dysfunction, hepatitis, cholestasis, jaundice, rash, skin itching, fever, nausea, vomiting, loss of appetite, malaise, elevated γ-GTP, elevated AST/ALT, elevated LDH, elevated ALP, neutropenia, pancytopenia, agranulocytosis, thrombocytopenia, pharyngitis, fever, lymphadenopathy, purpura, subcutaneous hemorrhage, leukopenia, anemia, rash, itching, photosensitivity reaction, mucocutaneous syndrome, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, erythema multiforme, toxic skin rash, exfoliative dermatitis, bullous dermatitis, psoriasis-like rash, worsening of psoriasis, hair loss, musculoskeletal reactions, arthralgia, myalgia, weakness, elevated CPK, rhabdomyolysis, hypotension, dyspnea, chest tightness, urticaria, erythema, facial edema, lymphangiectasia, abdominal distention, decreased appetite, indigestion, nausea, mild abdominal pain, diarrhea, gastric discomfort, thirst, vomiting, glossitis, depression, anxiety, headache, loss of taste, taste disorders, dizziness, drowsiness, sensory disturbances, sensory reduction, decreased attention, insomnia, elevated BUN, frequent urination, visual disturbances, tinnitus, anaphylactic reaction, angioedema, superficial erythematous lupus, elevated total cholesterol in the blood, increased triglyceride levels, malaise, tongue discoloration, palpitations, edema, menstrual irregularities, paralysis, systemic disorders, fever, fatigue, weight loss, anaphylactic reaction, serum sickness-like reaction, visual obscurity, decreased vision, hearing loss, auditory disorders, vasculitis, permanent loss of smell, anosmia, hyposmia, drug rash accompanied by eosinophilia and systemic symptoms, pancreatitis, rhabdomyolysis, influenza-like illness, increased serum creatine phosphokinase
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture from entering. The storage temperature should be maintained at room temperature between 1 degree and 30 degrees.
White to nearly off-white round tablets
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowTerbinafine Hydrochloride 140.625mg
Tablet · Prescription medication
Os Korea Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
GP Therapeutics Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Hutex Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Anguk Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Medica Korea Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Gyeongnam Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Daehwa Pharmaceutical Co., Ltd.
Terbinafine Hydrochloride 10mg
Cream · OTC medication
Korea Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.